A citation-based method for searching scientific literature

Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Pawel Domagala, Cezary Cybulski, Oleg Oszurek, Marek Szwiec, Karol Gugala, Malgorzata Stawicka, Zbigniew Morawiec, Tomasz Mierzwa, Hanna Janiszewska, Ewa Kilar, Elzbieta Marczyk, Beata Kozak-Klonowska, Monika Siolek, Dariusz Surdyka, Rafal Wisniowski, Michal Posmyk, Ping Sun, Jan Lubinski, Steven A Narod. J Clin Oncol 2013
Times Cited: 78







List of co-cited articles
499 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Gad Rennert, Shantih Bisland-Naggan, Ofra Barnett-Griness, Naomi Bar-Joseph, Shiyu Zhang, Hedy S Rennert, Steven A Narod. N Engl J Med 2007
206
42

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Pamela J Goodwin, Kelly-Anne Phillips, Dee W West, Marguerite Ennis, John L Hopper, Esther M John, Frances P O'Malley, Roger L Milne, Irene L Andrulis, Michael L Friedlander,[...]. J Clin Oncol 2012
98
39

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
378
23

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman, Bryony Eccles, Sue Gerty, Lorraine T Durcan, Louise Jones,[...]. Lancet Oncol 2018
163
23

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin,[...]. Breast Cancer Res 2004
212
21

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
21

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
355
21

Prognosis of BRCA-associated breast cancer: a summary of evidence.
L Bordeleau, S Panchal, P Goodwin. Breast Cancer Res Treat 2010
78
20

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
20

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
17

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
L C Verhoog, C T Brekelmans, C Seynaeve, L M van den Bosch, G Dahmen, A N van Geel, M M Tilanus-Linthorst, C C Bartels, A Wagner, A van den Ouweland,[...]. Lancet 1998
359
17

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
114
17

Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.
Alexandra J van den Broek, Marjanka K Schmidt, Laura J van 't Veer, Rob A E M Tollenaar, Flora E van Leeuwen. PLoS One 2015
52
26

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Banu Arun, Soley Bayraktar, Diane D Liu, Angelica M Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton, Vicente Valero, Funda Meric-Bernstam, Gabriel N Hortobagyi,[...]. J Clin Oncol 2011
112
16

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
362
16

Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
D Stoppa-Lyonnet, Y Ansquer, H Dreyfus, C Gautier, M Gauthier-Villars, E Bourstyn, K B Clough, H Magdelénat, P Pouillart, A Vincent-Salomon,[...]. J Clin Oncol 2000
139
16

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Marjanka K Schmidt, Alexandra J van den Broek, Rob A E M Tollenaar, Vincent T H B M Smit, Pieter J Westenend, Mariël Brinkhuis, Wolter J W Oosterhuis, Jelle Wesseling, Maryska L Janssen-Heijnen, Jan J Jobsen,[...]. J Natl Cancer Inst 2017
38
34

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Soley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K Litton, E Lin, Constance T Albarracin, Funda Meric-Bernstam, Ana M Gonzalez-Angulo,[...]. Breast Cancer Res Treat 2011
67
17

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
148
15

Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Zora Baretta, Simone Mocellin, Elena Goldin, Olufunmilayo I Olopade, Dezheng Huo. Medicine (Baltimore) 2016
81
15

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
882
14

Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.
Laura Cortesi, Cristina Masini, Claudia Cirilli, Veronica Medici, Isabella Marchi, Giovanna Cavazzini, Giuseppe Pasini, Daniela Turchetti, Massimo Federico. BMC Cancer 2010
29
37

Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis.
Eun-Ha Lee, Sue K Park, Boyoung Park, Sung-Won Kim, Min Hyuk Lee, Sei Hyun Ahn, Byung Ho Son, Keun-Young Yoo, Daehee Kang. Breast Cancer Res Treat 2010
58
18

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Larissa J Lee, Brian Alexander, Stuart J Schnitt, Amy Comander, Bridget Gallagher, Judy E Garber, Nadine Tung. Cancer 2011
52
21

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
528
11

Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Pal Moller, D Gareth Evans, Marta M Reis, Helen Gregory, Elaine Anderson, Lovise Maehle, Fiona Lalloo, Anthony Howell, Jaran Apold, Neal Clark,[...]. Int J Cancer 2007
68
13

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Kelly Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T Lynch, Carrie Snyder, Nadine Tung, Charmaine Kim-Sing, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. BMJ 2014
165
11

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
11

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
11

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
10


Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Kelly Metcalfe, Henry T Lynch, William D Foulkes, Nadine Tung, Charmaine Kim-Sing, Olufunmilayo I Olopade, Andrea Eisen, Barry Rosen, Carrie Snyder, Shelley Gershman,[...]. JAMA Oncol 2015
67
11

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
185
10

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
Jon G Jonasson, Olafur A Stefansson, Oskar T Johannsson, Helgi Sigurdsson, Bjarni A Agnarsson, Gudridur H Olafsdottir, Kristin K Alexiusdottir, Hrefna Stefansdottir, Rodrigo Munoz Mitev, Katrin Olafsdottir,[...]. Br J Cancer 2016
26
30

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
T Byrski, T Huzarski, R Dent, J Gronwald, D Zuziak, C Cybulski, J Kladny, B Gorski, J Lubinski, S A Narod. Breast Cancer Res Treat 2009
225
8

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
733
8

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
S Bayraktar, A M Gutierrez-Barrera, H Lin, N Elsayegh, T Tasbas, J K Litton, N K Ibrahim, P K Morrow, M Green, V Valero,[...]. Clin Exp Metastasis 2013
23
30

BRCA1 and BRCA2: 1994 and beyond.
Steven A Narod, William D Foulkes. Nat Rev Cancer 2004
609
8

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
366
8

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.
Andrea Veronesi, Clelia de Giacomi, Maria D Magri, Davide Lombardi, Martina Zanetti, Cristina Scuderi, Riccardo Dolcetti, Alessandra Viel, Diana Crivellari, Ettore Bidoli,[...]. BMC Cancer 2005
60
11

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
8

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Christian F Singer, Pal Moller, Henry T Lynch, Susan Armel, Beth Karlan, William D Foulkes, Susan L Neuhausen,[...]. J Natl Cancer Inst 2016
134
8

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
762
8

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
7

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
Tomasz Byrski, Rebecca Dent, Pawel Blecharz, Malgorzata Foszczynska-Kloda, Jacek Gronwald, Tomasz Huzarski, Cezary Cybulski, Elzbieta Marczyk, Robert Chrzan, Andrea Eisen,[...]. Breast Cancer Res 2012
135
7

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
S R Lakhani, J Jacquemier, J P Sloane, B A Gusterson, T J Anderson, M J van de Vijver, L M Farid, D Venter, A Antoniou, A Storfer-Isser,[...]. J Natl Cancer Inst 1998
511
7

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
William D Foulkes, Kelly Metcalfe, Ping Sun, Wedad M Hanna, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Olufunmilayo I Olopade, Barbara L Weber, Jane McLennan,[...]. Clin Cancer Res 2004
223
7

Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
W D Foulkes, N Wong, J S Brunet, L R Bégin, J C Zhang, J J Martinez, F Rozen, P N Tonin, S A Narod, S E Karp,[...]. Clin Cancer Res 1997
95
7

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
W D Foulkes, P O Chappuis, N Wong, J S Brunet, D Vesprini, F Rozen, Z Q Yuan, M N Pollak, G Kuperstein, S A Narod,[...]. Ann Oncol 2000
68
8



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.